Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

NHS Ordered To Cover Gilead’s HIV Drug In Court Ruling

XTALKS VITALS NEWS

Court Ruling

As the PrEP is a preventive drug, the NHS argued that it should not be required to cover a patient’s costs associated with the treatment.

Tweetables from this article:

Tweet: Pre-exposure prophylaxis (PrEP) drug – called Truvada – has a 92 percent success rate of preventing HIV infection http://ctt.ec/DdXae+Pre-exposure prophylaxis (PrEP) drug – called Truvada – has a 92 percent success rate of preventing HIV infection.

Tweet: NHS estimates that PrEP drug could cost as much as $26 million per year http://ctt.ec/E2bb6+NHS estimates that PrEP drug could cost as much as $26 million per year.

Share this!

August 5, 2016 | by Sarah Massey, M.Sc.

A London high court ruled that England’s National Health Service (NHS) must cover Gilead’s HIV treatment. The pre-exposure prophylaxis (PrEP) drug – called Truvada – has a 92 percent success rate of preventing HIV infection in those individuals who are at-risk of being exposed to the virus.

As the PrEP is a preventive drug, the NHS argued that it should not be required to cover a patient’s costs associated with the treatment. However, the court ruled that the treatment must be covered by the NHS because no barriers – whether financial or legal – stand in the way of them paying for the drug. The NHS has since appealed the court’s ruling.

In July, the PrEP was recommended for approval by the Committee for Medicinal Products – a division of the European Medicines Agency (EMA) – however, the treatment could be costly. The NHS estimates that the drug could cost as much as $26 million per year.

Because of its effectiveness at preventing HIV infection, the National AIDS Trust, amongst other HIV advocacy groups, are great supporters of the treatment. While the HIV prevention data for Truvada comes from clinical trials conducted in the US, a UK-based study – known as the Pre-Exposure Option for Reducing HIV in the U.K.: Immediate or Deferred (PROUD) – has also confirmed the efficacy of the drug.



A total of 545 at-risk men took part in the PROUD study, which evaluated the efficacy of immediate or delayed treatment with the PrEP. The first treatment group began receiving Truvada immediately, while the second group waited to begin treatment a year after the study commenced. The study investigators found that three high-risk men in the first treatment group became infected with HIV, compared to 19 men in the second group.

“Over 4,000 people are getting HIV every year in the UK—we desperately need further prevention options to add to condom use,” said Deborah Gold, Chief Executive of the National AIDS Trust. “PrEP works. It saves money and it will make an enormous difference to the lives of men and women across the country who are at risk of acquiring HIV. The delay to commissioning PrEP is both unethical and expensive.”

Though the NHS will appeal the decision, it plans to investigate how PrEP could be covered in a cost-effective manner through its partnership with Public Health England. According to a press release issued by the health provider, the NHS will also consider less-expensive treatments with similar clinical results. Should these alternative treatments come up short, Gilead “will be asked to submit better prices, which would clearly affect the likelihood that their drug could be commissioned.”


Keywords: HIV, NHS, Preventive Medicine


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.